Orchestra BioMed Holdings Inc (NASDAQ: OBIO) on Friday, soared 4.23% from the previous trading day, before settling in for the closing price of $2.6. Within the past 52 weeks, OBIO’s price has moved between $2.37 and $7.04.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -273.68% over the past five years. The company achieved an average annual earnings per share of -19.65%. With a float of $33.45 million, this company’s outstanding shares have now reached $38.31 million.
Let’s look at the performance matrix of the company that is accounted for 70 employees. In terms of profitability, gross margin is 92.58%, operating margin of -2383.89%, and the pretax margin is -2297.85%.
Orchestra BioMed Holdings Inc (OBIO) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Orchestra BioMed Holdings Inc is 30.40%, while institutional ownership is 40.40%. The most recent insider transaction that took place on Aug 01 ’25, was worth 1,925,000. In this transaction 10% Owner of this company bought 700,000 shares at a rate of $2.75, taking the stock ownership to the 5,292,556 shares. Before that another transaction happened on Aug 04 ’25, when Company’s insider bought 20,000 for $2.75, making the entire transaction worth $55,000. This insider now owns 349,331 shares in total.
Orchestra BioMed Holdings Inc (OBIO) Latest Financial update
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.45 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.4) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.52 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -19.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.30% during the next five years compared to -273.68% drop over the previous five years of trading.
Orchestra BioMed Holdings Inc (NASDAQ: OBIO) Trading Performance Indicators
Orchestra BioMed Holdings Inc (OBIO) is currently performing well based on its current performance indicators. A quick ratio of 3.34 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 45.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.77, a number that is poised to hit -0.50 in the next quarter and is forecasted to reach -1.74 in one year’s time.
Technical Analysis of Orchestra BioMed Holdings Inc (OBIO)
Orchestra BioMed Holdings Inc (NASDAQ: OBIO) saw its 5-day average volume 0.61 million, a positive change from its year-to-date volume of 0.29 million. As of the previous 9 days, the stock’s Stochastic %D was 19.27%.
During the past 100 days, Orchestra BioMed Holdings Inc’s (OBIO) raw stochastic average was set at 14.13%, which indicates a significant decrease from 24.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.19 in the past 14 days, which was lower than the 0.27 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.03, while its 200-day Moving Average is $4.17.
